Neuroprotection in Stroke
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE - page 2
- About the CNS pharmaceutical analysis team - page 2
- CHAPTER 1 EXECUTIVE SUMMARY - page 5
- Introduction - page 5
- Scope and coverage of the Brief - page 5
- Key findings about neuroprotection in stroke - page 6
- Successful neuroprotection is limited by the short window of opportunity for active intervention. Manufacturers need to work with this by: a) looking for compounds that are effective over a more extended period of time; and b) mobilizing the public, patients and medical community to ensure that stroke victims are treated within the optimum period. - page 6
- The cascade of cell death is multi-faceted and although simple single-target mechanisms have shown some efficacy in preclinical trials, a more complex multi-targeted approach may prove more successful in patients. By developing a greater understanding of the processes and timelines between injury and neuronal death, companies may find that not only do multi-targeted drugs have potential, but also a therapeutic regime may need to be developed involving a number of different products with varying mechanisms of action, administered at the appropriate time in the degenerative cascade or recovery period. - page 8
- CHAPTER 2 PATIENT POTENTIAL - page 11
- Definition of syndrome - page 11
- Risk factors - page 11
- Epidemiology and impact - page 12
- Incidence - page 13
- US - page 13
- Japan - page 14
- Europe - page 14
- France - page 14
- Germany - page 14
- Italy - page 15
- Spain - page 15
- UK - page 15
- Summary - page 16
- Future trends - page 17
- CHAPTER 3 CURRENT CLINICAL PRACTICE - page 19
- Diagnosis - page 19
- Treatment - page 20
- Non-pharmacological treatment - page 20
- Pharmacological treatment - page 21
- Preventative therapy - page 21
- Acute treatment - page 21
- Unmet needs of current therapies - page 24
- Poor patient awareness - page 24
- Delays in accessing optimum treatment by emergency medical teams - page 25
- Drugs with longer than three-hour window - page 26
- What are the implications for future market players? - page 27
- CHAPTER 4 NEUROPROTECTION - page 28
- Role of neuroprotection in stroke - page 28
- Trials for neuroprotective drugs - page 30
- Glutamate antagonists - page 30
- GABAA agonists - page 31
- Ion channel modulators - page 31
- Free-radical scavengers - page 32
- Other strategies - page 33
- Opioids - page 33
- Potassium channel activators - page 33
- Pipeline products - page 33
- Citicoline - page 36
- Cerovive (NXY-059) - page 37
- Tacrolimus - page 38
- ONO-2506 - page 39
- Semax - page 40
- DP-b99 - page 40
- SUN-N4057 - page 42
- Traxoprodil (CP-101606) - page 42
- BIII-890-CL - page 42
- Recently discontinued products - page 42
- Branosyn (repinotan) (BAY x3702) - page 42
- Future market outlook - page 44
- Go back to basics - page 44
- Switch focus to combination therapies - page 45
- APPENDIX - page 47
- Bibliography - page 47
- Websites - page 51
- Disclaimer - page 54
- List of Tables
- Table 1: Population with first ischemic stroke across the seven major markets, 2004 - page 17
- Table 2: Compounds in development as potential neuroprotectants in stroke, 2004 - page 35
- List of Figures
- Figure 1: The ischemic cascade - page 29
Other users found this report page using the following search terms: stroke neuroprotection stroke neuroprotection cascade ischemic neuroprotective treatment what review recovery future
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.